M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Here is some other vaccine news of note for the week.
After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.
The £20 million series A backed by GV will help Vaccitech develop an MVA-vectored universal flu vaccine currently in phase 2.
Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.
China's ApolloBio increased upfront payment, while also terminating its right to buy into Inovio.
Sanofi's recent loss in C. diff is a win for Pfizer and Valneva, which boast their own late-stage candidates, according to GlobalData.
Here's some other vaccine news of note for the week.
VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.